Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07280312 · ClinicalTrials.gov registry record · NA
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
A NA study of Ovarian Neoplasms and Ovarian Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07280312: Recruiting NA study of Ovarian Neoplasms and Ovarian Carcinoma, sponsored by Mayo Clinic.
NCT07280312 is a NA study of Ovarian Neoplasms and Ovarian Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07280312, a NA study of Ovarian Neoplasms and Ovarian Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment for their ovarian or adnexal lesions as part of their clinical care. Ovarian cancer is the most lethal gynecologic malignancy, often diagnosed at an advanced stage. Current diagnostic tools include a blood test (serum cancer antigen 125 \[CA125\]) and transvaginal ultrasound. However, CA125 has limited diagnostic accuracy and is Food and Drug Administration-approved only for monitoring the return of cancer (recurrence), not for preoperative diagnosis. A key measurement in calculating ovarian and adnexal cancer risk is by looking at increased blood flow, which may suggest a higher risk of cancer developing. However, current ultrasound techniques have limited ability to assess blood flow. A new ultrasound technique, UMI, may have higher sensitivity for detecting small blood vessels compared to traditional ultrasound imaging.
Primary Outcome
Ovarian-Adnexal Reporting and Data System (O-RADS) scores will be initially based on B-mode and Doppler imaging (standard of care) obtained prior to surgical treatment. Radiologists will then review ultrasound microvessel imaging (UMI) images and may choose to revise the score. Accuracy of score adjustments will be assessed using final pathology results from the participant's medical record.
Conditions Studied
Interventions
- PROCEDURE Transvaginal Ultrasound
- PROCEDURE Ultrasound Microvessel Imaging
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2029-12-17 |
| Phase | NA |
What NCT07280312 shows while recruiting
NCT07280312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (89% lower).
The record links to 6 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Transvaginal Ultrasound is the first listed.
NCT07280312 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07280312 about?
NCT07280312 is a clinical study titled "Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions". This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment for their ovarian or adnexal lesions as part of their clinical care. Ovarian cancer is the most lethal gynecologic malign...
What is the current status of trial NCT07280312?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-01-22. Estimated completion is 2029-12-17.
What conditions does trial NCT07280312 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Ovarian Carcinoma, Female Reproductive System Neoplasm, Female Reproductive System Adnexal Neoplasm, Adnexal Lesion.
What interventions are being tested in trial NCT07280312?
The interventions under investigation include: Transvaginal Ultrasound (PROCEDURE), Ultrasound Microvessel Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT07280312?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07280312 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07280312's enrollment target sits among peer trials
40 32nd of 38 higher than 7 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
COMPLETED · NA
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
RECRUITING
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI